Werewolf Therapeutics (HOWL) vs Serina Therapeutics (SER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Werewolf Therapeutics (HOWL) has outperformed Serina Therapeutics (SER) over the past year, losing 45.0% versus a loss of 64.2%. Over five years, SER leads with a -93.9% price change compared with -94.3% for HOWL. Serina Therapeutics is the larger company by market cap ($50.8 million vs $47.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HOWL | SER |
|---|---|---|
| Share price | $0.9796 | $2.00 |
| Market cap | $47.61M | $50.80M |
| 1-day change | +7.65% | -0.50% |
| YTD return | +54.51% | +4.55% |
| 1-year return | -44.97% | -64.16% |
| 5-year return | -94.26% | -93.91% |
| EPS (TTM) | $-0.79 | $-1.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.85 | $5.60 |
| 52-week low | $0.27 | $1.22 |
| Distance from 52-week high | -47.05% | -64.29% |
| Analyst consensus | none | none |
| Avg. price target upside | +614.58% | +375.00% |
| Average volume | 6.80M | 63.89K |
| Shares outstanding | 48.60M | 25.40M |
| Employees | 39 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HOWL has outperformed SER by 19.2 percentage points over the past year.
About Werewolf Therapeutics
HOWL stock →Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
About Serina Therapeutics
SER stock →Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
HOWL vs SER FAQ
Which is bigger, Werewolf Therapeutics or Serina Therapeutics?
Serina Therapeutics (SER) is larger, with a market capitalization of $50.80M compared with $47.61M for Werewolf Therapeutics (HOWL).
Which stock has performed better over the past year, HOWL or SER?
HOWL returned -44.97% over the past 12 months, compared with -64.16% for SER (price return, excluding dividends). Past performance does not predict future results.
Are Werewolf Therapeutics and Serina Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.